# Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma

> **NCT05507775** · NA · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Non-Medullary Thyroid Carcinoma

## Interventions

- **DRUG:** Digoxin tablet

## Key facts

- **NCT ID:** NCT05507775
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-06
- **Primary completion:** 2023-06-21
- **Final completion:** 2024-01-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507775, "Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05507775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*